(COG AAML1031) A Phase 3 Randomized Trial for Patients with de novo AML Using Bortezomib and Sorafenib (IND#114480; NSC#681239, NSC#724772) for Patients with High Allelic Ratio FLT3/ITD
To compare event free survival and overall survival in patients with de novo acute myeloid leukemia (AML) without high allelic ratio FLT3/ITD + mutations who are randomized to standard therapy versus bortezomib/standard combination therapy. To determine the feasibility of combining bortezomib with standard chemotherapy in patients with de nova AML.
Study Number: 

NCG 217112

Principal Investigator: 
ClinicalTrials.Gov ID: 

To inquire about participating in these studies, call 1-877-ASK-RPCI (1-877-275-7724) or e-mail askrpci@roswellpark.org.